Literature DB >> 15860191

[Gene therapy: current situation and expectations].

R Alemany Bonastre1, J Barquinero Máñez, S Ramón y Cajal Agueras.   

Abstract

In this review the current situation of gene therapy is described in hematological diseases, immunological conditions, and cancer. In all of them, the principal objective of various approaches with gene therapy is transduction of therapeutic genes in most of target cells. In chronic or immunological diseases, a stable expression of therapeutic genes is also required; in tumor cells, the efficiency or percentage of transduced cells make conditional on the treatment success. Consequently, vectors are one of the basic elements to optimize gene therapy approaches and protocols in view of the facts that we know that with liposomes less than 10% of cells are transduced, that retrovirus only infect cells in replication, and that adenovirus give rise to an important inflammatory response and a transitory transduction of the therapeutic gene. In addition recent approaches in cancer gene therapy with selective replication virus, suicidal genes, etc., are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15860191      PMCID: PMC7130155          DOI: 10.1157/13074166

Source DB:  PubMed          Journal:  Rev Clin Esp        ISSN: 0014-2565            Impact factor:   1.556


  21 in total

Review 1.  Clinical update of Ad-p53 gene therapy for lung cancer.

Authors:  Stephen G Swisher; Jack A Roth
Journal:  Surg Oncol Clin N Am       Date:  2002-07       Impact factor: 3.495

2.  Polyclonal long-term repopulating stem cell clones in a primate model.

Authors:  Manfred Schmidt; Philipp Zickler; Gesa Hoffmann; Sebastian Haas; Manuela Wissler; Arne Muessig; John F Tisdale; Ken Kuramoto; Robert G Andrews; Tong Wu; Hans-Peter Kiem; Cynthia E Dunbar; Christof von Kalle
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

3.  Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression.

Authors:  H S Pandha; L A Martin; A Rigg; H C Hurst; G W Stamp; K Sikora; N R Lemoine
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

4.  Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene.

Authors:  T Puig; E Kádár; A Limón; J A Cancelas; H Eixarch; L Luquín; M García; J Barquinero
Journal:  Gene Ther       Date:  2002-11       Impact factor: 5.250

Review 5.  Replicative adenoviruses for cancer therapy.

Authors:  R Alemany; C Balagué; D T Curiel
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

Review 6.  Gene therapy: reality or myth for the global bleeding disorders community?

Authors:  K Kelley; I Verma; G F Pierce
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

7.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

Authors:  Bruno Sangro; Guillermo Mazzolini; Juan Ruiz; Maite Herraiz; Jorge Quiroga; Ignacio Herrero; Alberto Benito; Javier Larrache; Jesus Pueyo; Jose Carlos Subtil; Cristina Olagüe; Josu Sola; Belén Sádaba; Carlos Lacasa; Ignacio Melero; Cheng Qian; Jesus Prieto
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

8.  Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.

Authors:  Carlos Parada; Javier Hernández Losa; Juan Guinea; Víctor Sánchez-Arévalo; Víctor Fernández Soria; Luis Alvarez-Vallina; Ricardo Sánchez-Prieto; Santiago Ramón y Cajal
Journal:  Cancer Gene Ther       Date:  2003-02       Impact factor: 5.987

9.  Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.

Authors:  Janice E Bowman; Jane S Reese; Karen T Lingas; Stanton L Gerson
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

10.  Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts.

Authors:  S O Peters; E L Kittler; H S Ramshaw; P J Quesenberry
Journal:  Exp Hematol       Date:  1995-05       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.